3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
481
Leukemia
287
Precursor Cell Lymphoblastic Leukemia-Lymphoma
249
Leukemia, Lymphocytic, Chronic, B-Cell
235
Myelodysplastic Syndromes
200
Lymphoma
148
Lymphoma, Non-Hodgkin
143
Hematologic Neoplasms
139
Recurrence
109
Lymphoma, Mantle-Cell
102
Lymphoma, Follicular
100
Lymphoma, Large B-Cell, Diffuse
96
Multiple Myeloma
82
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
81
Leukemia, Myelomonocytic, Chronic
77
Lymphoma, B-Cell, Marginal Zone
75
Burkitt Lymphoma
72
Hodgkin Disease
69
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
52
Lymphoma, B-Cell
50
Neoplasms
47
Waldenstrom Macroglobulinemia
46
Myeloproliferative Disorders
44
Blast Crisis
41
Lymphoma, Large-Cell, Immunoblastic
38
Leukemia, Myeloid, Chronic-Phase
35
Leukemia, B-Cell
34
Leukemia, Myeloid, Accelerated Phase
33
Congenital Abnormalities
32
Leukemia, Biphenotypic, Acute
31
Interventions
olorofim
1
Caspofungin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Invasive Pulmonary Aspergillosis
×
Other hematologic neoplasm
×
Clear all
NCT02856178
2018-02-15
SAFEGUARD
F2G Biotech GmbH
Phase 1/2
Withdrawn